Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy
<p>Abstract</p> <p>Objective</p> <p>To examine the efficacy of different radiation doses after achievement of a complete response to chemotherapy in diffuse large B-cell lymphoma (DLBCL).</p> <p>Methods</p> <p>Patients with stage I-IV DLBCL treat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-06-01
|
| Series: | Radiation Oncology |
| Online Access: | http://www.ro-journal.com/content/7/1/100 |
| _version_ | 1819036112771874816 |
|---|---|
| author | Dorth Jennifer A Prosnitz Leonard R Broadwater Gloria Beaven Anne W Kelsey Chris R |
| author_facet | Dorth Jennifer A Prosnitz Leonard R Broadwater Gloria Beaven Anne W Kelsey Chris R |
| author_sort | Dorth Jennifer A |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Objective</p> <p>To examine the efficacy of different radiation doses after achievement of a complete response to chemotherapy in diffuse large B-cell lymphoma (DLBCL).</p> <p>Methods</p> <p>Patients with stage I-IV DLBCL treated from 1995–2009 at Duke Cancer Institute who achieved a complete response to chemotherapy were reviewed. In-field control, event-free survival, and overall survival were calculated using the Kaplan-Meier method. Dose response was evaluated by grouping treated sites by delivered radiation dose.</p> <p>Results</p> <p>105 patients were treated with RT to 214 disease sites. Chemotherapy (median 6 cycles) was R-CHOP (65%), CHOP (26%), R-CNOP (2%), or other (7%). Post-chemotherapy imaging was PET/CT (88%), gallium with CT (1%), or CT only (11%). The median RT dose was 30 Gy (range, 12–40 Gy). The median radiation dose was higher for patients with stage I-II disease compared with patients with stage III-IV disease (30 versus 24.5 Gy, p < 0.001). Five-year in-field control, event-free survival, and overall survival for all patients was 94% (95% CI: 89-99%), 84% (95% CI: 77-92%), and 91% (95% CI: 85-97%), respectively. Six patients developed an in-field recurrence at 10 sites, without a clear dose response. In-field failure was higher at sites ≥ 10 cm (14% versus 4%, p = 0.06).</p> <p>Conclusion</p> <p>In-field control was excellent with a combined modality approach when a complete response was achieved after chemotherapy without a clear radiation dose response.</p> |
| first_indexed | 2024-12-21T08:00:21Z |
| format | Article |
| id | doaj.art-81077228c5694ef089601521d60b61ff |
| institution | Directory Open Access Journal |
| issn | 1748-717X |
| language | English |
| last_indexed | 2024-12-21T08:00:21Z |
| publishDate | 2012-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj.art-81077228c5694ef089601521d60b61ff2022-12-21T19:10:55ZengBMCRadiation Oncology1748-717X2012-06-017110010.1186/1748-717X-7-100Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapyDorth Jennifer AProsnitz Leonard RBroadwater GloriaBeaven Anne WKelsey Chris R<p>Abstract</p> <p>Objective</p> <p>To examine the efficacy of different radiation doses after achievement of a complete response to chemotherapy in diffuse large B-cell lymphoma (DLBCL).</p> <p>Methods</p> <p>Patients with stage I-IV DLBCL treated from 1995–2009 at Duke Cancer Institute who achieved a complete response to chemotherapy were reviewed. In-field control, event-free survival, and overall survival were calculated using the Kaplan-Meier method. Dose response was evaluated by grouping treated sites by delivered radiation dose.</p> <p>Results</p> <p>105 patients were treated with RT to 214 disease sites. Chemotherapy (median 6 cycles) was R-CHOP (65%), CHOP (26%), R-CNOP (2%), or other (7%). Post-chemotherapy imaging was PET/CT (88%), gallium with CT (1%), or CT only (11%). The median RT dose was 30 Gy (range, 12–40 Gy). The median radiation dose was higher for patients with stage I-II disease compared with patients with stage III-IV disease (30 versus 24.5 Gy, p < 0.001). Five-year in-field control, event-free survival, and overall survival for all patients was 94% (95% CI: 89-99%), 84% (95% CI: 77-92%), and 91% (95% CI: 85-97%), respectively. Six patients developed an in-field recurrence at 10 sites, without a clear dose response. In-field failure was higher at sites ≥ 10 cm (14% versus 4%, p = 0.06).</p> <p>Conclusion</p> <p>In-field control was excellent with a combined modality approach when a complete response was achieved after chemotherapy without a clear radiation dose response.</p>http://www.ro-journal.com/content/7/1/100 |
| spellingShingle | Dorth Jennifer A Prosnitz Leonard R Broadwater Gloria Beaven Anne W Kelsey Chris R Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy Radiation Oncology |
| title | Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy |
| title_full | Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy |
| title_fullStr | Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy |
| title_full_unstemmed | Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy |
| title_short | Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy |
| title_sort | radiotherapy dose response analysis for diffuse large b cell lymphoma with a complete response to chemotherapy |
| url | http://www.ro-journal.com/content/7/1/100 |
| work_keys_str_mv | AT dorthjennifera radiotherapydoseresponseanalysisfordiffuselargebcelllymphomawithacompleteresponsetochemotherapy AT prosnitzleonardr radiotherapydoseresponseanalysisfordiffuselargebcelllymphomawithacompleteresponsetochemotherapy AT broadwatergloria radiotherapydoseresponseanalysisfordiffuselargebcelllymphomawithacompleteresponsetochemotherapy AT beavenannew radiotherapydoseresponseanalysisfordiffuselargebcelllymphomawithacompleteresponsetochemotherapy AT kelseychrisr radiotherapydoseresponseanalysisfordiffuselargebcelllymphomawithacompleteresponsetochemotherapy |